“…Moreover, no significant difference was observed in the richness and Shannon diversity of intestinal microbiota in NSCLC patients between pre-therapy (T1) and post-therapy (T2, T3, T4, T5, T6, T7, T8, T9, T10) ( P > 0.05, Supplementary Table S4 ), indicating that osimertinib therapy did not play great roles in alpha diversity of intestinal microbiota. However, we found that there was significantly different in beta diversity between pre-therapy and post-therapy in NSCLC patients based on the dissimilar test ( P < 0.05, Supplementary Table S5 ), suggesting that osimertinib therapy has made the intestinal microbial community composition changed from the whole ( Zhuang et al, 2019 ). At the same time, there was a little separation among NSCLC samples with different treatment cycles, and between healthy individuals and NSCLC patients ( Figure 4 ).…”